There is good news today for lung cancer patients. The FDA has announced that it has approved expansion of the immunotherapy drug nivolumab (Opdivo) for certain lung cancer patients.
Julie Brahmer, M.D., oncologist at the Johns Hopkins Kimmel Cancer Center and director of its Thoracic Oncology Program, is one of the leaders of the initial, first-in-human trial of nivolumab and ongoing clinical trials that the FDA reviewed in its decision today to approve nivolumab for advanced squamous cell lung cancer. She says, "This is an exciting development for lung cancer patients today. We're entering a new era of treatment, notably, the first time immunotherapy has shown improved survival outcomes compared to chemotherapy and the first time any type of immunotherapy for lung cancer has been approved. We hope it's the first step to more immune-targeted treatments for lung cancer patients."
Is immunotherapy effective for advanced metastatic thyroid cancer?
According to our experts, no immunotherapy drugs have yet been approved by the FDA for use in thyroid cancer; however, many large cancer centers like ours are conducting early phase clinical trials of various immunotherapy strategies for many forms of advanced cancers, including thyroid cancer.
The article was encouraging. I was in the Baltimore area and stopped by the clinic to get a consult for brother that has stage 4 Lung Cancer and Brain Tumor, time is precious. Very disappointing not getting a call back.
Hello Mr. Morrison,
This field is, indeed, encouraging. I'm sorry to hear that you didn't get a call that you were expecting. Please message me directly at wasta@jhmi.edu with the details, and I'd be glad to help get your message to our lung cancer coordinators.
Thank you,
Vanessa
Comments are closed.